Latest Capital Raises News

Rimfire Pacific Mining has secured $3.5 million through a discounted share placement to accelerate scandium resource development across its NSW projects, signaling renewed momentum after arbitration setbacks.

Amplia Therapeutics has launched a $27.5 million capital raising to advance its lead drug Narmafotinib, a promising FAK inhibitor showing superior efficacy in pancreatic cancer trials. The funds will support ongoing and new clinical studies, positioning the company for pivotal regulatory milestones.

Amplia Therapeutics has successfully raised A$25 million through an institutional placement and launched a A$2.5 million Share Purchase Plan to fund pivotal clinical trials of its lead drug narmafotinib. The capital injection positions the company to advance key pancreatic and ovarian cancer studies into 2027.

IperionX has successfully commissioned its Virginia titanium manufacturing campus, secured a substantial U.S. Department of Defense contract, and raised $46 million to fast-track production expansion through 2030.

Lake Resources has raised $2.1 million through its At-the-Market facility by issuing 65 million shares to Acuity Capital, while extending the agreement to 2031 to support its Kachi Project and working capital needs.

Meteoric Resources has successfully raised $42.5 million through an oversubscribed placement, underpinning its push towards a Final Investment Decision for the Caldeira Rare Earth Project in 2026.

Latrobe Magnesium Limited has addressed ASX concerns over recent share price and volume spikes, attributing the market activity to recognition of its asset value and the imminent start of its demonstration plant.

IperionX has secured A$70 million through a share placement to fast-track expansion of its titanium production capacity in the U.S., aligning closely with Department of Defense priorities.

Cygnus Metals reports standout drilling results at its Chibougamau project, highlighting the new Golden Eye prospect and Corner Bay deposit, supported by a strong A$18.3 million capital raise to accelerate development.

Macarthur Minerals has updated its rights issue prospectus, introducing a cap on the underwriter's shareholding and revising key offer terms. These changes aim to balance funding needs with shareholder control and regulatory compliance.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart technology, reporting promising clinical results in Crohn’s disease and GVHD, alongside a $3.5 million capital raise to fuel next-stage development.

Elsight Limited has raised A$60 million through a strongly supported placement, marking a milestone with consecutive record revenues and cash flow breakeven. The company is poised to capitalize on surging defence budgets and expanding drone markets with a robust pipeline of opportunities.